Automatic Detection and Classification of Ca2+ Release Events in Confocal Line- and Frame-scan Images

Analysis of Ca2+ signals obtained in various cell types (i.e. cardiomyocytes) is always a trade-off between acquisition speed and signal-to-noise ratio of the fluorescence signal. This becomes especially apparent during fast two- or three-dimensional confocal imaging when local intracellular fluorescence signals originating from Ca2+ release from intracellular Ca2+ stores (e.g. sarcoplasmic reticulum, SR) need to be examined. Mathematical methods have been developed to remedy a high noise level by fitting each pixel with a transient function to "denoise" the image.

http://bit.ly/2EOr4PO

Lipid-conjugated rigidochromic probe discloses membrane alteration in model cells of Krabbe disease

The plasma membrane of cells has a complex architecture based on the bi-dimensional liquid-crystalline bilayer arrangement of phospho- and sphingolipids, which in turn embeds several proteins and is connected to the cytoskeleton. Several studies highlight the spatial membrane organization into more ordered (Lo or lipid raft) and more disordered (Ld) domains. We here report on a fluorescent analog of the green fluorescent protein (GFP) chromophore that, when conjugated to a phospholipid, enables the quantification of the Lo and Ld domains in living cells on account of its large fluorescence lifetime variation in the two phases.

http://bit.ly/2EKLGHN

LincRNA-p21 Inhibits Cell Viability and Promotes Cell Apoptosis in Parkinson’s Disease through Activating -Synuclein Expression

Long intergenic noncoding RNA-p21 (lincRNA-p21) has been reported to be increased in Parkinson's disease (PD). However, the function and underlying mechanisms of lincRNA-p21 remain not clear. In order to explore the role of lincRNA-p21 in PD, we used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to induce in vivo PD model (C57BL/6 mice) and utilized N-methyl-4-phenylpyridinium (MPP+) to create in vitro PD model (SH-SY5Y cells). Results showed that the expression level of lincRNA-p21 was increased significantly in PD models. High abundance of lincRNA-p21 inhibited viability and promoted apoptosis markedly in SH-SY5Y cells treated with MPP+. Mechanistically, further experiments demonstrated that upregulation of lincRNA-p21 could sponge miR-1277-5p and indirectly increase the expression of α-synuclein to suppress viability and activate apoptosis in SH-SY5Y cells. In short, our study illustrated that lincRNA-p21/miR-1277-5p axis regulated viability and apoptosis in SH-SY5Y cells treated with MPP+ via targeting α-synuclein. LincRNA-p21 might be a novel target for PD.

http://bit.ly/2SjKY8d

Eugene L. Gottlieb, 1919-2018

Eugene Louis Gottlieb, founding editor of the Journal of Clinical Orthodontics, died peacefully at his home in Sedona, Arizona, on October 11, at age 99, after a brief illness.

http://bit.ly/2LxDmMW

Anterior open bite correction with 2-jaw orthognathic surgery

A 26-year-old man with an anterior open bite was treated with orthodontics combined with 2-jaw surgery. Total treatment time was 19 months. Both his occlusion and facial appearance were significantly improved by the surgical-orthodontic treatment.

http://bit.ly/2LxUG4b

Effects of time and clear aligner removal frequency on the force delivered by different polyethylene terephthalate glycol-modified materials determined with thin-film pressure sensors

Many factors influence the force changes of clear aligners. The purpose of this study was to identify the various factors that influence the force changes generated by polyethylene terephthalate glycol-modified (PET-G) materials. Therefore, a force measurement system based on a flexible thin-film pressure sensor was established.

http://bit.ly/2rS9v8M

Directory: AAO Officers and Organizations

http://bit.ly/2LxUF07

Resin-modified glass ionomer cement vs composite for orthodontic bonding: A multicenter, single-blind, randomized controlled trial

In this study, we aimed to compare the incidence of new demineralized lesions and bond failures between 2 groups of participants wearing fixed orthodontic appliances bonded with either light-cured resin-modified glass ionomer cement or light-cured composite.

http://bit.ly/2rTvRXt

Information for readers

http://bit.ly/2LxUCRZ

Lip position analysis of young women with different skeletal patterns during posed smiling using 3-dimensional stereophotogrammetry

The aim of this study was to explore the internal relationship between posed smile characteristics, lip position, and skeletal patterns in young women.

http://bit.ly/2rSMjHB

Editorial Board

http://bit.ly/2LxUBNV

Survival rate of two orthodontic bonded retainer wires

We read the article "Clinical effectiveness of two orthodontic retainer wires on mandibular arch retention" (Gunay F, Oz A. Am J Orthod Dentofacial Orthop 2018; 153:232-8) with great interest. We congratulate the authors for conducting a robust study with an effective study design on this important topic. However, we would seek certain clarifications from the authors on several points:

http://bit.ly/2rU7Y28

Table of Contents

http://bit.ly/2LD5hew

Influence of the hyrax expander screw position on stress distribution in the maxilla: A study with finite elements

Our objective was to evaluate the stress and deformation distribution patterns on the maxillary bone structure using the finite element method by simulation of different vertical and anteroposterior positions of the expansion screw on the hyrax expander appliance.

http://bit.ly/2rS9wtm

January 2019

http://bit.ly/2Lz4c7d

Intention-to-treat analysis: Are we managing dropouts and missing data properly in research on orthodontic treatment? A systematic review

Intention-to-treat (ITT) analysis is an approach to managing dropouts and missing data in randomized controlled trials (RCTs). In this study, we systematically reviewed orthodontic RCTs to assess the frequency that an ITT analysis was carried out, to compare the number of trials that reported using ITT analyses with those that had truly used it, and to evaluate how dropouts and missing data were managed.

http://bit.ly/2rS9uBK

The influence of variables on predicting growth patterns of adolescents with varying skeletal patterns

The article "Mandibular condyle bone density in adolescents with varying skeletal patterns evaluated using CBCT: A potential predictive tool" (Kim K-J, Park JH, Bay RC, Lee M-Y, Chang N-Y, Chae J-M. Am J Orthod Dentofacial Orthop 2018;154:382-9) addresses some controversial issues in orthodontics that we would like to comment on:

http://bit.ly/2LyKHMb

Effectiveness of incremental vs maximum bite advancement during Herbst appliance therapy in late adolescent and young adult patients

The purpose of this research was to compare the effects of Herbst appliance therapy using incremental vs maximum advancement in late adolescent and young adult patients with Class II skeletal malocclusion.

http://bit.ly/2rRgZca

Authors' response

Thank you very much for your interest in our article. We appreciate your insightful questions and valuable suggestion.

http://bit.ly/2LxUt0T

Peer Reviewers

http://bit.ly/2rSiyXd

Patient with asymmetric multiple hypodontia treated with autotransplantation of 2 premolars

Tooth autotransplantation is performed in patients with congenitally missing teeth and those with traumatic tooth loss. We report a course of edgewise treatment of a girl with multiple congenitally missing teeth and residual features of ectodermal dysplasia, who was treated with autotransplantation of 2 premolars with developing roots. She was 8 years old at the beginning of the treatment. No signs of inflammation, root resorption, or pulp symptoms were observed during the 2.5 years of edgewise treatment after autotransplantation.

http://bit.ly/2rUgJt0

Robert J. Isaacson, 1932-2018

Robert J. Isaacson, a leading orthodontic educator, researcher, and scholar, passed away peacefully at the age of 86 on September 15, 2018, near his home in Wayzata, Minnesota. Bob was born in Flushing, New York, on July 12, 1932, and grew up in New Jersey. He was a proud graduate of the University of Minnesota where he earned his BS, DDS, MSD, and PhD degrees from 1950 to 1962. He served as a Captain in the US Army from 1956 to 1958. He joined the faculty of the University of Minnesota in the Department of Orthodontics in 1962, beginning a distinguished orthodontic career.

http://bit.ly/2LxSFFm

Activity and morphologic changes in the mandible after mandibular osteotomy

Orthognathic surgery accelerates orthodontic tooth movement, and tooth movement accelerates with demineralized bone and accelerated bone remodeling. The purpose of this study was to ascertain whether orthognathic surgery induces accelerated bone remodeling. The research design included a human model and an animal model.

http://bit.ly/2rSRZ4c

Table of Contents

http://bit.ly/2SimrAl

Editorial Board

http://bit.ly/2AgAT4T

Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma

Amplification of MYCN plays a pivotal role in multiple types of tumors and correlates with poor prognosis in high-risk neuroblastoma. Despite recent advances in the treatment of neuroblastoma, no approaches directly target the master oncogene MYCN. Difficulties in targeting the MYCN protein inspired us to develop a new gene level inhibitory strategy using a sequence-specific gene regulator. Here we generated a MYCN-targeting pyrrole-imidazole (PI) polyamide, MYCN-A3, which directly binds to and alkylates DNA at homing motifs within the MYCN transcript. Pharmacological suppression of MYCN inhibited the proliferation of cancer cells harboring MYCN amplification compared with MYCN non-amplified cancer cells. In neuroblastoma xenograft mouse models, MYCN-A3 specifically downregulated MYCN expression and suppressed tumor progression with no detectable adverse effects and resulted in prolonged overall survival. Moreover, treatment with MYCN-A3, but not MYCN non-targeting PI polyamide, precipitated a copy number reduction of MYCN in neuroblastoma cells with MYCN amplification. These findings suggest that directly targeting MYCN with MYCN-A3 is a novel therapeutic approach to reduce copy number of the MYCN gene for MYCN-amplified neuroblastoma.

http://bit.ly/2EMKy7d

Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis

Dipeptidyl peptidase (DPP)-4 is a multifunctional glycoprotein involved in various biological and pathological processes. DPP-4 has been widely recognized as a therapeutic target for type 2 diabetes mellitus but is also implicated in the development of human malignancies. Here we show that inhibition of DPP-4 accelerates breast cancer metastasis via induction of CXCL12/CXCR4, which activates mTOR to promote epithelial-mesenchymal transition (EMT). In cultured cells, DPP-4 knockdown induced EMT and cell migration. Treatment with the DPP-4 inhibitor KR62436 (KR) promoted primary tumor growth and lung metastasis in a 4T1 tumor allograft mouse model; DPP-4 knockdown in 4T1 cells displayed similar phenotypes in vivo and in vitro. KR treatment enhanced the levels of CXCL12/CXCR4 and phosphorylated mTOR, which were associated with the induction of EMT in metastatic cancer cells. KR-induced EMT in cancer cells was inhibited by treatment with the CXCR4 inhibitor AMD3100 or the mTOR inhibitor rapamycin, and AMD3100 suppressed KR-induced metastasis in vivo. Our findings suggest that DPP-4 plays a significant role in cancer biology and that inhibition of DPP-4 promotes cancer metastasis via induction of the CXCL12/CXCR4/mTOR/EMT axis.

http://bit.ly/2EHEQTs

A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related hepatocellular carcinoma

Hepatocellular carcignogenesis is attributed to the reprogramming of cellular metabolism as consequence of the alteration in metabolite-related gene regulation. Identifying the mechanism of aberrant metabolism is of great potential to provide novel targets for the treatment of hepatocellular carcinoma (HCC). Here, we demonstrated that glycogen synthase 2 (GYS2) restricted tumor growth in HBV-related HCC via a negative feedback loop with p53. Expression of GYS2 was significantly downregulated in HCC and correlated with decreased glycogen content and unfavorable patient outcomes. GYS2 overexpression suppressed, whereas GYS2 knockdown facilitated cell proliferation in vitro and tumor growth in vivo via modulating p53 expression. GYS2 competitively bound to MDM2 to prevent p53 from MDM2-mediated ubiquitination and degradation. Furthermore, GYS2 enhanced the p300-induced acetylation of p53 at K373/382, which in turn inhibited the transcription of GYS2 in the support of HBx/HDAC1 complex. In summary, our findings suggest that GYS2 serves as a prognostic factor and functions as a tumor suppressor in HCC. The newly identified HBx/GYS2/p53 axis is responsible for the deregulation of glycogen metabolism and represents a promising therapeutic target for the clinical management of HCC.

http://bit.ly/2ELOIfz

Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study’

Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study'

Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study', Published online: 25 December 2018; doi:10.1038/s41416-018-0203-x

Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study'

https://go.nature.com/2VcdhaL

Response to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study”

Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study"

Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study", Published online: 25 December 2018; doi:10.1038/s41416-018-0344-y

Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study"

https://go.nature.com/2Q21Hec

Exam 1: Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review

http://bit.ly/2BFcYMA

New Insights into Infections due to Multidrug Resistant Gram Negative Bacteria: The Interplay between Lab and Clinic

http://bit.ly/2AdL9v0

Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

Objectives. Pharmacokinetics studies recommend increasing efavirenz dosage in tuberculosis/HIV patients using rifampicin. We aimed to evaluate efficacy and safety of 600 versus 800 mg of efavirenz in tuberculosis/HIV patients using rifampicin. Design. We conducted an open label, multicentre, randomized trial from 2006 to 2012. The primary outcome was the proportion of undetectable viral load (HIV-VL) within six months. Secondary outcomes were time to achieve primary endpoint, trajectories of HIV-VL, proportion of any adverse events (AE), proportion of severe and serious AE (SSAE), and time to treatment interruption due to SSAE. Methods. Efavirenz-naïve patients were randomized 30 days after rifampicin-containing regimens initiation to receive 600 (comparison arm) or 800 mg (intervention arm) efavirenz-based regimens and followed-up for 180 days. Results. Sixty-five and 67 participants were respectively included in the comparison and intervention arms with 64.6% (52.5%-65.1%) and 62.7% (50.7%-73.3%) attaining undetectable HIV-VL in six months. Median time to attain undetectable HIV-VL was 70 days in both arms, with HIV-VL overlapping trajectories during follow-up. Cough, acne, and dizziness were more frequent in the intervention arm. SSAE were observed in 19.1% (13.8%-25.8%) and 25.0% (18.9%-33.2%), respectively. Survival curves up to the first SSAE-attributed treatment interruption were similar. None of the differences were statistically significant. Conclusion. Efficacy of efavirenz was similar regardless of dosage. Differences regarding safety occurred as mild and transient events, which did not interfere with treatment. Similar efficacy and safety (SSAE) and lower tolerance (minor AE) in the intervention group favour the use of 600 mg efavirenz in patients using rifampicin.

http://bit.ly/2SktPvl

Testing Novel Payment and Delivery Approaches Through the Veterans Health Administration's New Center for Innovation

The recently established Center for Innovation for Care and Payment will give the U.S. Department of Veterans Affairs (VA) the ability to test novel payment and service delivery models; will facilitate the VA's shift toward value-based coverage strategies, with a greater emphasis on population health; and will empower the VA to collaborate with other payers to drive improvements in quality, costs, and efficiency. The authors discuss these opportunities as well as the risks for unintended consequences.

http://bit.ly/2BCm38R

Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure A Meta-analysis of Randomized Controlled Trials

Background:

Atrial fibrillation (AF) and heart failure (HF) frequently coexist and are associated with increased morbidity and mortality risk.

Purpose:

To compare benefits and harms between catheter ablation and drug therapy in adult patients with AF and HF.

Data Sources:

ClinicalTrials.gov, PubMed, Web of Science (Clarivate Analytics), EBSCO Information Services, Cochrane Central Register of Controlled Trials, Google Scholar, and various scientific conference sessions from 1 January 2005 to 1 October 2018.

Study Selection:

Randomized controlled trials (RCTs) published in English that had at least 6 months of follow-up and compared clinical outcomes of catheter ablation versus drug therapy in adults with AF and HF.

Data Extraction:

2 investigators independently extracted data and assessed study quality.

Data Synthesis:

6 RCTs involving 775 patients met inclusion criteria. Compared with drug therapy, AF ablation reduced all-cause mortality (9.0% vs. 17.6%; risk ratio [RR], 0.52 [95% CI, 0.33 to 0.81) and HF hospitalizations (16.4% vs. 27.6%; RR, 0.60 [CI, 0.39 to 0.93]). Ablation improved left ventricular ejection fraction (LVEF) (mean difference, 6.95% [CI, 3.0% to 10.9%]), 6-minute walk test distance (mean difference, 20.93 m [CI, 5.91 to 35.95 m]), peak oxygen consumption (Vo₂max) (mean difference, 3.17 mL/kg per minute [CI, 1.26 to 5.07 mL/kg per minute]), and quality of life (mean difference in Minnesota Living with Heart Failure Questionnaire score, −9.02 points [CI, −19.75 to 1.71 points]). Serious adverse events were more common in the ablation groups, although differences between the ablation and drug therapy groups were not statistically significant (7.2% vs. 3.8%; RR, 1.68 [CI, 0.58 to 4.85]).

Limitation:

Results driven primarily by 1 clinical trial, possible patient selection bias in the ablation group, lack of patient-level data, open-label trial designs, and heterogeneous follow-up length among trials.

Conclusion:

Catheter ablation was superior to conventional drug therapy in improving all-cause mortality, HF hospitalizations, LVEF, 6-minute walk test distance, Vo₂max, and quality of life, with no statistically significant increase in serious adverse events.

Primary Funding Source:

None.

http://bit.ly/2QOPmzy

A Central Venous Catheter That Cannot Be Dislodged Easily by a Confused Patient

http://bit.ly/2ReMvzf

Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105000 UK women in the Generations Study’

https://go.nature.com/2T76ey7

Response to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study”

https://go.nature.com/2CwKC91

Reply

Aly and Mohamed have submitted itemized comments on the summary of the NIH sponsored workshop on bronchopulmonary dysplasia (BPD). The comments reflect on the definition of BPD and its implications. A well-recognized concern is that all currently used definitions only include the oxygen and ventilatory treatments being delivered at a single gestational age, generally 36 weeks postconceptional age.1 There are currently no objective assessments of alveolar, vascular, and airway injuries. The inadequacy of using the therapy to define the disease can be resolved only with the development of predictive biomarkers and imaging technologies to better phenotype BPD.

http://bit.ly/2SlVtIm

Contingencies on the workshop for bronchopulmonary dysplasia classification

We read with interest the executive summary of the workshop on bronchopulmonary dysplasia (BPD).1 The authors provided a comprehensive review on the incidence and pathogenesis of BPD and summarized the historical aspects in the definition of BPD. The workshop suggested refining the definition of BPD to include different grades based on the amount of respiratory support that an infant receives.

http://bit.ly/2AbGtp5

Vit C for Pregnant Smokers May Improve Newborn Lung Function

MONDAY, Dec. 24, 2018 -- For pregnant smokers, vitamin C supplementation may improve newborn lung function, according to a study published online Dec. 7 in the American Journal of Respiratory and Critical Care Medicine. Cindy T. McEvoy, M.D., from...

http://bit.ly/2V9xC00

EMS Treatment for Possible Heart Attack Varies by Sex

MONDAY, Dec. 24, 2018 -- Disparities exist in the emergency medical services (EMS) treatment of women and men with chest pain (CP) or out-of-hospital cardiac arrest (OHCA), according to a study published online Dec. 10 in Women's Health...

http://bit.ly/2V8oUiL

Costs, Expected Weight Loss Impact Bariatric Surgery Choice

MONDAY, Dec. 24, 2018 -- For patients considering bariatric surgery, costs, expected weight loss, and resolution of medical conditions are the most important characteristics driving surgery decisions, according to a study published online Nov. 28 in...

http://bit.ly/2PXOseE

FDA Approves Drugs for Treatment of Two Rare Blood Diseases

MONDAY, Dec. 24, 2018 -- Two drugs have been approved by the U.S. Food and Drug Administration for the treatment of rare blood diseases, the agency announced Friday. Elzonris (tagraxofusp-erzs) infusion was granted the first approval for the...

http://bit.ly/2Q0h6vC

HPV Ups Cervical Cancer Risk, Even With No Cellular Signs

MONDAY, Dec. 24, 2018 -- The presence of certain high-risk human papillomavirus (HPV) types predicts future risk for high-grade cervical cancer even among women with no cellular indications of cancer at baseline, according to a study published...

http://bit.ly/2V8zK8k

Clinical evaluation of a newly developed graft inserter (NS Endo-Inserter) for Descemet stripping automated endothelial keratoplasty

http://bit.ly/2QOb4DQ

Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study

http://bit.ly/2BF6D3B

The human skin microbiota is a rich source of bacteriocin producing staphylococci which kill human pathogens

Abstract

The demand for novel antimicrobial therapies due to the threat posed by antimicrobial resistance has resulted in a growing interest in the protective role of our skin bacteria, and the importance of competition between bacteria on the skin. A survey of the cultivable bacteria on human skin was undertaken to identify the capacity of the skin microbiota to produce bacteriocins with activity against skin pathogens. Twenty-one bacteriocins produced by bacteria isolated from seven sites from each subject exhibited inhibition spectra ranging from broad to narrow range, inhibiting many Gram-positive bacteria, including opportunistic skin pathogens such as Propionibacterium acnes (recently renamed Cutibacterium acnes), Staphylococcus epidermidis, and methicillin-resistant Staphylococcus aureus (MRSA). Sequencing indicated that the antimicrobial-producing isolates were predominately species/strains of the Staphylococcus genus. Colony mass spectrometry revealed peptide masses which do not correspond to known bacteriocins. In an era where antibiotic resistance is of major concern, the inhibitory effect of novel bacteriocins from bacteria of skin origin demonstrates the antimicrobial potential that could be harnessed from within the human skin microbiota.

http://bit.ly/2GGz5b5

Cancers, Vol. 11, Pages 19: Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine

Cancers, Vol. 11, Pages 19: Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine

Cancers doi: 10.3390/cancers11010019

Authors: Marta Tellez-Gabriel Denis Cochonneau Marie Cadé Camille Jubellin Marie-Françoise Heymann Dominique Heymann

The main cause of death from cancer is associated with the development of metastases, resulting from the inability of current therapies to cure patients at metastatic stages. Generating preclinical models to better characterize the evolution of the disease is thus of utmost importance, in order to implement effective new cancer biomarkers and therapies. Circulating Tumor Cells (CTCs) are good candidates for generating preclinical models, making it possible to follow up the spatial and temporal heterogeneity of tumor tissues. This method is a non-invasive liquid biopsy that can be obtained at any stage of the disease. It partially summarizes the molecular heterogeneity of the corresponding tumors at a given time. Here, we discuss the CTC-derived models that have been generated so far, from simplified 2D cultures to the most complex CTC-derived explants (CDX models). We highlight the challenges and strengths of these preclinical tools, as well as some of the recent studies published using these models.

http://bit.ly/2ENjyEQ

Corrigendum to “A 12-Week Assessment of the Treatment of White Spot Lesions with CPP-ACP Paste and/or Fluoride Varnish”

http://bit.ly/2GGvVEf

Anomalies of the genitourinary tract in children with 22q11.2 deletion syndrome

The 22q11.2 deletion syndrome (22q11.2DS) involves multiple organ systems with variable phenotypic expression. Genitourinary tract abnormalities have been noted to be present in up to 30–40% of patients. At our institution, an internationally recognized, comprehensive, and multidisciplinary 22q11.2DS care center has been providing care to these children. We sought to report on the incidence of genitourinary tract anomalies in this large cohort and, therefore, retrospectively reviewed all patients who underwent a complete evaluation from 1992 to March 2017. We identified all children with any genital or urinary tract anomaly. For all children with a diagnosis of hydronephrosis, the underlying etiology was determined, when possible. Overall, 1,073 of 1,267 children with 22q11.2DS underwent renal evaluations at our institution. Hundered Sixty‐Two (15.1%) children had structural abnormalities of their kidneys/urinary tracts. The majority of children with hydronephrosis (63%) had isolated upper tract dilation without any additional diagnoses. Boys were significantly more likely to be diagnosed with a genital abnormality than girls (7.7 vs. 0.5%, p < 0.001). Of the 649 boys in the entire cohort, 24 (3.7%) had cryptorchidism and 24 (3.7%) had hypospadias, which was noted to be mild in all except one boy. Overall, findings of hydronephrosis, unilateral renal agenesis, and multicystic dysplastic kidney occur at higher rates than expected in the general population. Given these findings, in addition to routine physical examination, we believe that all patients with 22q11.2DS warrant screening RBUS at time of diagnosis.

http://bit.ly/2BBqj8B

Disseminated Mucormycosis with Positive Aspergillus Galactomannan

We describe a case of disseminated mucormycosis (Apophysomyces elegans) diagnosed on autopsy, in a man who had been working in construction with undiagnosed neutropenia from hairy-cell leukemia, which is rarely associated with invasive mold infections. Galactomannan values in both blood and bronchoalveolar lavage were strongly positive. There is an unmet need for accurate noninvasive fungal diagnostic tests. Detailed history, including occupational exposures, can be more informative than laboratory workup.

http://bit.ly/2PZxGf6

A Case of Parvovirus-Related Haemophagocytic Lymphohistiocytosis in a Patient with HbH Disease

Hemophagocytic lymphohistiocytosis (HLH) is rare and life-threatening medical emergency. Parvovirus infection is rarely associated with HLH. We report a case of parvovirus-related HLH in a patient with alpha thalassaemia (HbH disease). The patient responded well to a course of dexamethasone without the need of etoposide. Based on our literature search, this is the first case of parvovirus related HLH in a patient with HbH disease in the medical literature.

http://bit.ly/2T69Q3e

CHECK UP ΑΛΛΕΡΓΙΑΣ,ΒΑΣΙΚΟΣ ΕΛΕΓΧΟΣ ΑΛΛΕΡΓΙΑΣ ΓΙΑ ΠΑΙΔΙΑ κ' ΕΝΗΛΙΚΕΣ,Ελληνικά Αλλεργιογόνα

ΒΑΣΙΚΟΣ ΕΛΕΓΧΟΣ ΑΛΛΕΡΓΙΑΣ ΓΙΑ ΠΑΙΔΙΑ κ' ΕΝΗΛΙΚΕΣ
E1 ΤΡΙΧΩΜΑ ΓΑΤΑΣ (Felis domesticus)
F2 ΓΑΛΑ ΑΓΕΛΑΔΟΣ
F13 ΦΥΣΤΙΚΙ ΑΡΑΠΙΚΟ (Arachis hypogaea)
F4 ΣΙΤΑΡΙ (Triticum aestivum)
F14 ΣΟΓΙΑ (Glycine max - Soja hispida)
F1 ΑΣΠΡΑΔΙ ΑΥΓΟΥ
F75 KΡΟΚΟΣ AΥΓΟΥ
D1 DERMATOPHAGOIDES PTERONYSSINUS
D2 DERMATOPHAGOIDES FARINAE
D3 DERMATOPHAGOIDES MICROCERAS
G6 ΦΛΕΟΝ ΤΟ ΛΕΙΜΩΝΙΟΝ / ΤΡΙΦΥΛΛΙ (Phleum pretense)
ΕΛΕΓΧΟΣ ΣΕ ΕΙΣΠΝΕΟΜΕΝΑ ΑΛΛΕΡΓΙΟΓΟΝΑ
D1 DERMATOPHAGOIDES PTERONYSSINUS
D2 DERMATOPHAGOIDES FARINAE
D3 DERMATOPHAGOIDES MICROCERAS
G6 ΦΛΕΟΝ ΤΟ ΛΕΙΜΩΝΙΟΝ / ΤΡΙΦΥΛΛΙ (Phleum pretense)
E1 ΤΡΙΧΩΜΑ ΓΑΤΑΣ (Felis domesticus)
E5 ΤΡΙΧΩΜΑ ΣΚΥΛΟΥ (Canis familiaris)
M2 Cladosporium herbarum
M3 Aspergillus fumigatus
M6 Alternaria alternata
W1 ΑΜΒΡΟΣΙΑ ΚΟΙΝΗ (Ambrosia elatior)
T3 ΣΗΜΥΔΑ (Betula verrucosa)



CHECK UP ΑΛΛΕΡΓΙΑΣ
ΕΛΕΓΧΟΣ ΑΛΛΕΡΓΙΑΣ ΣΕ ΤΡΟΦΙΜΑ
F1 ΑΣΠΡΑΔΙ ΑΥΓΟΥ
F75 KΡΟΚΟΣ AΥΓΟΥ
F2 ΓΑΛΑ ΑΓΕΛΑΔΟΣ
F78 KΑΖΕΪΝΗ ΓΑΛΑΚΤΟΣ
F26 XΟΙΡΙΝΟ ΚΡΕΑΣ (Sus sp.)
F27 ΜΟΣΧΑΡΙΣΙΟ ΚΡΕΑΣ (Bos sp.)
F83 ΚΟΤΟΠΟΥΛΟ (Gallus sp.)
F4 ΣΙΤΑΡΙ (Triticum aestivum)
F5 ΣΙΚΑΛΗ (Secale cereal)
F8 ΚΑΛΑΜΠΟΚΙ (Zea mays)
F9 ΡΥΖΙ (Oryza sativa)
F14 ΣΟΓΙΑ (Glycine max - Soja hispida)
F15 ΦΑΣΟΛΙ ΑΣΠΡΟ (Phaseolus vulgaris)
F25 NΤΟΜΑΤΑ (Lycopersicon lycopersicum)
F31 ΚΑΡΟΤΟ (Daucus carota)
F35 ΠΑΤΑΤΑ (Solanum tuberosum)
F48 KΡΕΜΜΥΔΙ (Allium cepa)
F85 ΣΕΛΙΝΟ (Apium graveolens)
F216 ΛΑΧΑΝΟ (Brassica oleracea capitata)
F49 MΗΛΟ (Malus domestica)
F92 MΠΑΝΑΝΑ (Musa sp.)
F33 ΠΟΡΤΟΚΑΛΙ (Citrus sinensis)
F95 ΡΟΔΑΚΙΝΟ (Prunus persica)
F44 ΦΡΑΟΥΛΑ (Fragaria vesca)
F20 AΜΥΓΔΑΛΟ (Amygdalus communis)
F13 ΦΥΣΤΙΚΙ ΑΡΑΠΙΚΟ (Arachis hypogaea)
F17 ΦΟΥΝΤΟΥΚΙ (Corylus avellana)
F256 ΚΑΡΥΔΙ (Juglans regia)
F45 MΑΓΙΑ (Saccharomyces cerevisiae)
F93 KΑΚΑΟ (Theobroma cacao)
F3 ΜΠΑΚΑΛΙΑΡΟΣ (Gadus morhua)
F24 ΓΑΡΙΔΑ (Pandalus borealis)
F41 ΣΟΛΩΜΟΣ (Salmo salar)
F40 TOΝΟΣ (Thunnus albacares)

ΕΛΕΓΧΟΣ ΑΛΛΕΡΓΙΑΣ ΣΕ ΞΗΡΟΥΣ ΚΑΡΠΟΥΣ
F10 ΣΟΥΣΑΜΙ (Sesamum indicum)
F13 ΦΥΣΤΙΚΙ ΑΡΑΠΙΚΟ (Arachis hypogaea)
F17 ΦΟΥΝΤΟΥΚΙ (Corylus avellana)
F18 ΦΥΣΤΙΚΙ ΒΡΑΖΙΛΙΑΝΙΚΟ (Bertholletia excelsa)
F20 AΜΥΓΔΑΛΟ (Amygdalus communis)
F183 ΗΛΙΟΣΠΟΡΟΣ (Helianthus annuus)
F201 ΠΕΚΑΝ (Carya illinoensis)
F202 ΚΑΣΙΟΥΣ (Anacardium occidentale)
F203 ΦΥΣΤΙΚΙ ΚΕΛΥΦΩΤΟ (Pistacia vera)
F256 ΚΑΡΥΔΙ (Juglans regia)
ΕΛΕΓΧΟΣ ΑΛΛΕΡΓΙΑΣ ΣΕ ΔΗΜΗΤΡΙΑΚΑ
F4 ΣΙΤΑΡΙ (Triticum aestivum)
F5 ΣΙΚΑΛΗ (Secale cereal)
F6 ΚΡΙΘΑΡΙ (Hordeum vulgare)
F7 ΒΡΩΜΗ (Avena sativa)

ΕΛΕΓΧΟΣ ΑΛΛΕΡΓΙΑΣ ΚΡΗΤΩΝ
M6 Alternaria alternata
E1 ΤΡΙΧΩΜΑ ΓΑΤΑΣ (Felis domesticus)
F1 ΑΣΠΡΑΔΙ ΑΥΓΟΥ
F2 ΓΑΛΑ ΑΓΕΛΑΔΟΣ
F13 ΦΥΣΤΙΚΙ ΑΡΑΠΙΚΟ (Arachis hypogaea)
D1 DERMATOPHAGOIDES PTERONYSSINUS
D2 DERMATOPHAGOIDES FARINAE
D3 DERMATOPHAGOIDES MICROCERAS
G5 ΗΡΑ ΠΟΛΥΕΤΗΣ (Lolium perenne)
G6 ΦΛΕΟΝ ΤΟ ΛΕΙΜΩΝΙΟΝ / ΤΡΙΦΥΛΛΙ (Phleum pretense)
T9 ΕΛΙΑ (Olea europaea)

ΚΑΤΑΛΟΓΟΣ ΑΛΛΕΡΓΙΟΓΟΝΩΝ

ΓΥΡΗ ΠΟΩΔΩΝ ΦΥΤΩΝ (GRASS POLLENS)
G1 ΑΝΘΟΞΑΝΘΟ / ΧΛΟΗ (Anthoxanthum odoratum)
G2 ΑΓΡΙΑΔΑ (Cynodon dactylon)
G3 ΔΑΚΤΥΛΙΔΑ / ΧΛΟΗ ΚΗΠΟΥ (Dactylis glomerata)
G4 ΧΛΟΗ ΛΙΒΑΔΙΟΥ / ΦΕΣΤΟΥΚΑ (Festuca elatior)
G5 ΗΡΑ ΠΟΛΥΕΤΗΣ (Lolium perenne)
G6 ΦΛΕΟΝ ΤΟ ΛΕΙΜΩΝΙΟΝ / ΤΡΙΦΥΛΛΙ (Phleum pretense)
G7 ΚΑΛΑΜΙ (Phragmites communis)
G8 ΛΕΙΒΑΔΟΠΟΑ ΛΕΙΑ (Poa pratensis)
G9 ΑΓΡΩΣΤΗ (Agrostis stolonifera)
G10 ΒΕΛΙΟΥΡΑΣ / ΣΟΡΓΟΝ (Sorghum halepense)
G11 AΓΡΙΟΒΡΩΜΗ (Bromus inermis)
G12 ΚΑΛΛΙΕΡΓΟΥΜΕΝΗ ΣΙΚΑΛΗ (Secale cereale)
G13 ΟΛΚΟΣ ΤΡΙΧΩΤΟΣ (Holcus lanatus)
G14 ΚΑΛΛΙΕΡΓΟΥΜΕΝΗ ΒΡΩΜΗ (Avena sativa)
G15 ΚΑΛΛΙΕΡΓΟΥΜΕΝΟ ΣΙΤΑΡΙ (Triticum aestivum)
G16 ΑΛΩΠΕΚΟΥΡΟΣ (Alopecurus pratensis)
G17 ΠΑΣΠΑΛΟΣ (Paspalum notatum)
G70 ΕΛΥΜΟΣ (Elymus triticoides)
G71 ΦΑΛΑΡΗ (Phalaris arundinacea)
G201 ΚΡΙΘΑΡΙ (Hordeum vulgare)
G202 ΚΑΛΑΜΠΟΚΙ (Zea mays)
G203 ΑΛΑΤΟΧΟΡΤΟ (Distichlis spicata)
G204 ΒΡΩΜΗ Η ΥΨΗΛΗ (Arrhenatherum elatius)

ΓΥΡΗ ΑΓΡΙΟΧΟΡΤΩΝ-ΖΙΖΑΝΙΩΝ (WEED POLLENS)
W1 ΑΜΒΡΟΣΙΑ ΚΟΙΝΗ (Ambrosia elatior)
W2 ΑΜΒΡΟΣΙΑ ΔΥΤΙΚΗ (Ambrosia psilostachya)
W3 ΑΜΒΡΟΣΙΑ (Ambrosia trifida)
W4 ΨΕΥΔΟΑΜΒΡΟΣΙΑ (Franseria acanthicarpa)
W5 ΑΨΙΘΙΑ (Artemisia absinthium)
W6 ΑΡΤΕΜΙΣΙΑ (Artemisia vulgaris)
W7 ΜΑΡΓΑΡΙΤΑ (Chrysanthemum leucanthemum)
W8 ΑΓΡΙΟΡΑΔΙΚΟ (Taraxacum vulgare)
W9 ΠΕΝΤΑΝΕΥΡΟ (Plantago lanceolata)
W10 ΛΟΥΒΟΥΔΙΑ (Chenopodium album)
W11 RUSSIAN THISTLE (Salsola kali)
W12 ΧΡΥΣΟΒΕΡΓΑ (Solidago virgaurea)
W13 ΞΑΝΘΙΟ (Xanthium commune)
W14 ΑΜΑΡΑΝΘΟΣ (Amaranthus retroflexus)
W16 ROUGH MARSH ELDER (Iva ciliata)
W17 ΚΟΧΙΑ (Kochia scoparia)
W18 ΛΑΠΑΘΟ (Rumex acetosa)
W19 ΠΕΡΔΙΚΑΚΙ (Parietaria officinalis)
W20 ΤΣΟΥΚΝΙΔΑ (Urtica dioica)
W21 ΠΕΡΔΙΚΑΚΙ (Parietaria judaica)
W22 ΑΣΙΑΤΙΚΟΣ ΛΥΚΙΣΚΟΣ (Humulus scandens)
W23 ΑΓΡΙΟΛΑΠΑΘΟ (Rumex crispus)
W45 ΜΗΔΙΚΗ (Medicago sativa)
W46 ΕΥΠΑΤΟΡΙΟ (Eupatorium capillifolium)
W82 ΑΜΑΡΑΝΘΟΣ PALMER (Amaranthus palmeri)
W203 ΕΛΑΙΟΚΡΑΜΒΗ (Brassica napus)
W204 ΗΛΙΑΝΘΟΣ (Helianthus annuus)
W206 ΧΑΜΟΜΗΛΙ (Matricaria chamomilla)
W207 ΛΟΥΠΙΝΟ (Lupinus sp.)
W210 ΖΑΧΑΡΟΤΕΥΤΛΟ (Beta vulgaris)

ΓΥΡΗ ΔΕΝΤΡΩΝ (TREE POLLENS)
T1 ΣΦΕΝΔΑΜΟΣ (Acer negundo)
T2 ΑΛΝΟΣ / ΣΚΛΗΘΡΑ (Alnus incana)
T3 ΣΗΜΥΔΑ (Betula verrucosa)
T4 ΦΟΥΝΤΟΥΚΙΑ (Corylus avellana)
T5 ΑΜΕΡΙΚΑΝΙΚΗ ΟΞΙΑ (Fagus grandifolia)
T6 ΚΕΔΡΟΣ ΒΟΥΝΟΥ / ΑΡΚΕΥΘΟΣ (Juniperus sabina)
T7 ΔΡΥΣ / ΒΕΛΑΝΙΔΙΑ (Quercus alba)
T8 ΦΤΕΛΙΑ (Ulmus americana)
T9 ΕΛΙΑ (Olea europaea)
T10 ΚΑΡΥΔΙΑ (Juglans californica)
T11 ΠΛΑΤΑΝΟS (Platanus acerifolia)
T12 IΤΙΑ (Salix caprea)
T14 ΛΕΥΚΑ (Populus deltoides)
T15 ΜΕΛΙΑ / ΦΡΑΞΟΣ (Fraxinus americana)
T16 ΛΕΥΚΟ ΠΕΥΚΟ (Pinus strobus)
T17 ΙΑΠΩΝΙΚΟΣ ΚΕΔΡΟΣ (Cryptomeria japonica)
T18 ΕΥΚΑΛΥΠΤΟΣ (Eucalyptus sp.)
T19 ΑΚΑΚΙΑ (Acacia longifolia)
T20 ΠΡΟΣΩΠΙΣ (Prosopis juliflora)
T21 ΜΑΛΑΛΕΥΚΗ (Melaleuca leucadendron)
T23 ΚΥΠΑΡΙΣΣΙ (Cupressus sempervirens)
T25 ΦΡΑΞΟΣ (Fraxinus excelsior)
T37 ΦΑΛΑΚΡΟ ΚΥΠΑΡΙΣΣΙ (Taxodium distichum)
T44 ΜΕΛΙΚΟΚΙΑ / ΚΕΛΤΙΣ (Celtis occidentalis)
T45 ΦΤΕΛΙΑ ΠΑΧΥΦΥΛΛΗ (Ulmus crassifolia)
T56 ΜΥΡΙΚΗ (Myrica cerifera)
T70 ΜΟΥΡΙΑ ΛΕΥΚΗ (Morus alba)
T71 ΜΟΥΡΙΑ ΕΡΥΘΡΗ (Morus rubra)
T72 ΚΟΚΟΦΟΙΝΙΚΑΣ (Arecastrum romanzoffianum)
T73 ΑΥΣΤΡΑΛΙΑΝΟ ΠΕΥΚΟ (Casuarina equisetifolia)
T201 ΕΡΥΘΡΕΛΑΤΗ (Picea abies)
T203 ΑΓΡΙΟΚΑΣΤΑΝΙΑ (Aesculus hippocastanum)
T205 ΚΟΥΦΟΞΥΛΙΑ (Sambucus nigra)
T206 ΚΑΣΤΑΝΙΑ (Castanea sativa)
T207 ΨΕΥΔΟΤΣΟΥΓΚΑ (Pseudotsuga taxifolia)
T208 ΦΛΑΜΟΥΡΙΑ (Tilia cordata)
T209 ΓΑΥΡΟΣ (Carpinus betulus)
T210 ΛΙΓΟΥΣΤΡΟ (Ligustrum vulgare)
T212 ΚΑΛΟΚΕΔΡΟΣ (Libocedrus decurrens)
T213 ΠΕΥΚΟ ΚΑΛΙΦΟΡΝΙΑΣ (Pinus radiata)
T214 ΦΟΙΝΙΚΑΣ ΚΑΝΑΡΙΟΣ (Phoenix canariensis)
T217 ΣΧΙΝΟΣ / ΨΕΥΔΟΠΙΠΕΡΙΑ (Schinus molle)
T222 ΚΥΠΑΡΙΣΣΙ ΑΡΙΖΟΝΑΣ (Cupressus arizonica)
T223 ΕΛΑΪΣ ΓΟΥΙΝΕΑΣ (Elaeis guineensis)

ΖΥΜΕΣ & ΜΥΚΗΤΕΣ
M1 Penicillium notatum
M2 Cladosporium herbarum
M3 Aspergillus fumigatus
M4 Mucor racemosus
M5 Candida albicans
M6 Alternaria alternata
M7 Botrytis cinerae
M8 Helminthosporium halodes
M9 Fusarium moniliforme
M10 Stemphylium botryosum
M11 Rhizopus nigricans
M12 Aureobasidium pullulans
M13 Phomae betae
M14 Epicoccum purpurascens
M15 Trichoderma viride
M16 Curvularia lunata

ΠΑΡΑΣΙΤΑ
P1 ΑΣΚΑΡΙΔΑ (Ascaris sp.)
P2 ΕΧΙΝΟΚΟΚΚΟΣ (Echinococcus sp.)

ΖΩΙΚΑ ΑΛΛΕΡΓΙΟΓΟΝΑ
E1 ΤΡΙΧΩΜΑ ΓΑΤΑΣ (Felis domesticus)
E3 ΤΡΙΧΩΜΑ ΑΛΟΓΟΥ (Equus caballus)
E4 ΤΡΙΧΩΜΑ ΑΓΕΛΑΔΟΣ (Bos taurus)
E5 ΤΡΙΧΩΜΑ ΣΚΥΛΟΥ (Canis familiaris)
E6 ΕΠΙΘΗΛΙΟ ΙΝΔΙΚΟΥ ΧΟΙΡΙΔΙΟΥ (Cavia porcellus)
E7 ΠΕΡΙΤΤΩΜΑΤΑ ΠΕΡΙΣΤΕΡΙΟΥ (Columba sp.)
E70 ΦΤΕΡΑ ΧΗΝΑΣ (Anser anser)
E71 EΠΙΘΗΛΙΟ ΠΟΝΤΙΚΟΥ (Mus sp.)
E72 ΠΡΩΤΕΪΝΕΣ ΟΥΡΩΝ ΠΟΝΤΙΚΟΥ (Mus sp.)
E73 ΕΠΙΘΗΛΙΟ ΑΡΟΥΡΑΙΟΥ (Rattus sp.)
E74 ΠΡΩΤΕΪΝΕΣ ΟΥΡΩΝ ΑΡΟΥΡΑΙΟΥ (Rattus sp.)
E75 ΠΡΩΤΕΪΝΕΣ ΟΡΟΥ ΑΡΟΥΡΑΙΟΥ (Rattus sp.)
E76 ΠΡΩΤΕΪΝΕΣ ΟΡΟΥ ΠΟΝΤΙΚΟΥ (Mus sp.)
E78 ΦΤΕΡΑ ΠΑΠΑΓΑΛΟΥ (Melopsittacus undulates)
E80 ΕΠΙΘΗΛΙΟ ΚΑΤΣΙΚΑΣ (Capra hircus)
E81 EΠΙΘΗΛΙΟ ΠΡΟΒΑΤΟΥ (Ovis sp.)
E82 ΕΠΙΘΗΛΙΟ ΚΟΥΝΕΛΙΟΥ (Oryctolagus cuniculus)
E83 ΕΠΙΘΗΛΙΟ ΓΟΥΡΟΥΝΙΟΥ (Sus domestica)
E84 ΕΠΙΘΗΛΙΟ ΧΑΜΣΤΕΡ (Cricetus sp., Mesocricetus sp.,Phodopus sp.)
E85 ΦΤΕΡΑ ΚΟΤΟΠΟΥΛΟΥ (Gallus domesticus)
E86 ΦΤΕΡΑ ΠΑΠΙΑΣ (Anas platyrhynca)
E89 ΦΤΕΡΑ ΓΑΛΟΠΟΥΛΑΣ (Meleagris gallopavo)
E201 ΦΤΕΡΑ ΚΑΝΑΡΙΝΙΟΥ (Serinus canaries)
E215 ΦΤΕΡΑ ΠΕΡΙΣΤΕΡΙΟΥ (Columba livia)

ΑΚΑΡΕΑ ΟΙΚΙΑΚΗΣ ΣΚΟΝΗΣ
D1 DERMATOPHAGOIDES PTERONYSSINUS
D2 DERMATOPHAGOIDES FARINAE
D3 DERMATOPHAGOIDES MICROCERAS
D70 ACARUS SIRUS
D71 LEPIDOGLYPHUS DESTRUCTOR
D72 TYROPHAGUS PUTRESCENTIAE
D73 GLYCYPHAGUS DOMESTICUS
D74 EUROGLYPHUS MAYNEI

ΟΙΚΙΑΚΗ ΣΚΟΝΗ
H1 ΟΙΚΙΑΚΗ ΣΚΟΝΗ / GREER LABS INC
H2 ΟΙΚΙΑΚΗ ΣΚΟΝΗ / HOLLISTER -STIER LABS
H3 ΟΙΚΙΑΚΗ ΣΚΟΝΗ / ΒENCARD
H4 ΟΙΚΙΑΚΗ ΣΚΟΝΗ / ALLERGOPHARMA
H6 ΟΙΚΙΑΚΗ ΣΚΟΝΗ / JAPAN

ΕΝΤΟΜΑ & ΔΗΛΗΤΗΡΙΑ ΕΝΤΟΜΩΝ
I1 ΔΗΛΗΤΗΡΙΟ ΜΕΛΙΣΣΑΣ (Apis mellifera)
I2 ΔΗΛΗΤΗΡΙΟ ΣΦΗΚΑΣ ΛΕΥΚΟΠΡΟΣΩΠΗΣ (Dolichovespula maculata)
I3 ΔΗΛΗΤΗΡΙΟ ΣΦΗΚΑΣ ΚΟΙΝΗΣ (Vespula sp.)
I4 ΔΗΛΗΤΗΡΙΟ ΣΦΗΚΑΣ ΧΑΡΤΙΟΥ (Polistes annularis)
I5 ΔΗΛΗΤΗΡΙΟ ΣΦΗΚΑΣ ΚΙΤΡΙΝΗΣ (Dolichovespula arenaria)
I6 ΚΑΤΣΑΡΙΔΑ (Blatella germanica)
I70 ΜΥΡΜΗΓΚΙ (Solenopsis invicta)
I71 ΚΟΥΝΟΥΠΙ (Aedes communis)
I75 ΔΗΛΗΤΗΡΙΟ ΣΦΗΚΑΣ ΕΥΡΩΠΑΪΚΗΣ (Vespa crabro)
I204 ΑΛΟΓΟΜΥΓΑ (Tabanus sp.)

ΦΑΡΜΑΚΑ
C1 ΠΕΝΙΚΙΛΛΙΝΗ G (Penicilloyl G)
C2 ΠΕΝΙΚΙΛΛΙΝΗ V (Penicilloyl V)
C5 ΑΜΠΙΚΙΛΛΙΝΗ (Ampicillin)
C6 ΑΜΟΞΙΚΙΛΛΙΝΗ (Amoxicillin)
C7 ΚΕΦΑΚΛΟΡΗ (Cephaclor)
C70 ΙΝΣΟΥΛΙΝΗ ΧΟΙΡΕΙΟΣ (Insulin, pig)
C71 ΙΝΣΟΥΛΙΝΗ ΒΟΕΙΟΣ (Insulin, bovine)
C73 ΙΝΣΟΥΛΙΝΗ ΑΝΘΡΩΠΙΝΗ (Insulin, human)
C209 ΧΥΜΟΠΑΠΑΪΝΗ (Chymopapain)

ΕΠΑΓΓΕΛΜΑΤΙΚΑ ΑΛΛΕΡΓΙΟΓΟΝΑ
K1 ΑΚΡΥΛΙΚΟ
K2 ΒΑΜΒΑΚΙ (ΚΑΤΕΡΓΑΣΜΕΝΟ)
K3 ΒΑΜΒΑΚΙ (ΑΚΑΤΕΡΓΑΣΤΟ)
K16 ΛΙΝΟ
K17 ΝΑΥΛΟΝ
K20 ΜΑΛΛΙ ΠΡΟΒΑΤΟΥ (ΚΑΤΕΡΓΑΣΜΕΝΟ)
K21 ΜΑΛΛΙ ΠΡΟΒΑΤΟΥ (ΑΚΑΤΕΡΓΑΣΤΟ)
K25 ΤΕΡΙΛΕΝ (ΤERYLENE)
K73 ΜΕΤΑΞΙ (Bombyx mori)
K75 ΙΣΟΚΥΑΝΙΚΟ ΑΛΑΣ TDI
K78 ΟΞΕΙΔΙΟ ΤΟΥ ΑΙΘΥΛΕΝΙΟΥ
K80 ΦΟΡΜΑΛΔΕΫΔΗ
K82 LATEX
K83 ΒΑΜΒΑΚΙ (ΣΠΟΡΟΙ)

ΔΙΑΦΟΡΑ ΑΛΛΕΡΓΙΟΓΟΝΑ
O70 ΣΠΕΡΜΑΤΙΚΟ ΠΛΑΣΜΑ

ΤΡΟΦΙΜΑ – ΦΡΟΥΤΑ
F33 ΠΟΡΤΟΚΑΛΙ (Citrus sinensis)
F44 ΦΡΑΟΥΛΑ (Fragaria vesca)
F49 MΗΛΟ (Malus domestica)
F84 AΚΤΙΝΙΔΙΟ (Actinidia deliciosa)
F87 ΠΕΠΟΝΙ (Cucumis melo)
F91 ΜΑΝΓΚΟ (Mangifera indica)
F92 MΠΑΝΑΝΑ (Musa sp.)
F94 ΑΧΛΑΔΙ (Pyrus communis)
F95 ΡΟΔΑΚΙΝΟ (Prunus persica)
F162 ΝΕΚΤΑΡΙΝΙ (Prunus persica v. nectarina)
F208 ΛΕΜΟΝΙ (Citrus limon)
F209 ΓΚΡΕΪΠΦΡΟΥΤ (Citrus paradisi)
F210 ΑΝΑΝΑΣ (Ananas comosus)
F211 ΜΑΥΡΟ ΜΟΥΡΟ (Rubus fruticosus)
F237 ΒΕΡΥΚΟΚΟ (Prunus armeniaca)
F242 KΕΡΑΣΙ (Prunus avium)
F255 ΔΑΜΑΣΚΗΝΟ (Prunus domestica)
F259 ΣΤΑΦΥΛΙ (Vitis venifera)
F288 ΜΥΡΤΙΛΛΟ (Vaccinium myrtillis)
F293 ΠΑΠΑΓΙΑ (Carica papaya)
F302 ΜΑΝΤΑΡΙΝΙ (Citrus reticulata)
F328 ΣΥΚΟ (Ficus carica)

ΤΡΟΦΙΜΑ – ΛΑΧΑΝΙΚΑ
F12 AΡΑΚΑΣ (Pisum sativum)
F25 NΤΟΜΑΤΑ (Lycopersicon lycopersicum)
F31 ΚΑΡΟΤΟ (Daucus carota)
F35 ΠΑΤΑΤΑ (Solanum tuberosum)
F47 ΣΚΟΡΔΟ (Allium sativum)
F48 KΡΕΜΜΥΔΙ (Allium cepa)
F51 ΜΠΑΜΠΟΥ ΒΛΑΣΤΟΣ (Phyllostachys pubescens)
F85 ΣΕΛΙΝΟ (Apium graveolens)
F96 ΑΒΟΚΑΝΤΟ (Persea americana)
F214 ΣΠΑΝΑΚΙ (Spinachia oleracea)
F215 MΑΡΟΥΛΙ (Lactuca sativa)
F216 ΛΑΧΑΝΟ (Brassica oleracea capitata)
F217 ΛΑΧΑΝΑΚΙ ΒΡΥΞΕΛΛΩΝ (Brassica oleracea gemmifera)
F225 ΚΟΛΟΚΥΘΑ (Curcubita pepo)
F244 ΑΓΓΟΥΡΙ (Cucumis sativum)
F260 ΜΠΡΟΚΟΛΟ (Brassica oleracea italica)
F261 ΣΠΑΡΑΓΓΙ (Asparagus officinalis)
F262 ΜΕΛΙΤΖΑΝΑ (Solanum melongena)
F276 ΜΑΡΑΘΟΣ (Foeniculum vulgare)
F291 ΚΟΥΝΟΥΠΙΔΙ (Brassica oleracea botrytis)
F315 ΦΑΣΟΛΙ ΠΡΑΣΙΝΟ (Phaseolus vulgaris)
F319 ΠΑΝΤΖΑΡΙ (Beta vulgaris)
F358 ΑΓΓΙΝΑΡΑ (Cynara scolymus)

ΤΡΟΦΙΜΑ – ΔΗΜΗΤΡΙΑΚΑ
F4 ΣΙΤΑΡΙ (Triticum aestivum)
F5 ΣΙΚΑΛΗ (Secale cereal)
F6 ΚΡΙΘΑΡΙ (Hordeum vulgare)
F7 ΒΡΩΜΗ (Avena sativa)
F8 ΚΑΛΑΜΠΟΚΙ (Zea mays)
F9 ΡΥΖΙ (Oryza sativa)
F11 ΦΑΓΟΠΥΡΟ (Fagopyrum esculentum)
F79 ΓΛΟΥΤΕΝΗ
F90 ΒΥΝΗ

ΤΡΟΦΙΜΑ – ΞΗΡΟΙ ΚΑΡΠΟΙ
F10 ΣΟΥΣΑΜΙ (Sesamum indicum)
F13 ΦΥΣΤΙΚΙ ΑΡΑΠΙΚΟ (Arachis hypogaea)
F17 ΦΟΥΝΤΟΥΚΙ (Corylus avellana)
F18 ΦΥΣΤΙΚΙ ΒΡΑΖΙΛΙΑΝΙΚΟ (Bertholletia excelsa)
F20 AΜΥΓΔΑΛΟ (Amygdalus communis)
F36 KΑΡΥΔΑ (Cocos nucifera)
F183 ΗΛΙΟΣΠΟΡΟΣ (Helianthus annuus)
F201 ΠΕΚΑΝ (Carya illinoensis)
F202 ΚΑΣΙΟΥΣ (Anacardium occidentale)
F203 ΦΥΣΤΙΚΙ ΚΕΛΥΦΩΤΟ (Pistacia vera)
F256 ΚΑΡΥΔΙ (Juglans regia)
F299 ΚΑΣΤΑΝΟ (Castanea sativa)

ΤΡΟΦΙΜΑ – ΟΣΠΡΙΑ
F14 ΣΟΓΙΑ (Glycine max - Soja hispida)
F15 ΦΑΣΟΛΙ ΑΣΠΡΟ (Phaseolus vulgaris)
F235 ΦΑΚΕΣ (Lens esculenta)
F309 ΡΕΒΙΘΙ (Cicer arietinus)

ΤΡΟΦΙΜΑ – ΜΠΑΧΑΡΙΚΑ
F86 MΑΙΝΤΑΝΟΣ (Petroselinum crispum)
F89 MOΥΣΤΑΡΔΑ (Brassica / Sinapis sp.)
F218 ΠΑΠΡΙΚΑ (Capsicum annuum)
F234 BΑΝΙΛΙΑ (Vanilla planifolia)
F277 ΑΝΙΘΟΣ (Anethum graveolens)
F281 ΚΑΡΥ
F332 ΜΕΝΤΑ (Mentha piperita)

ΤΡΟΦΙΜΑ – ΘΑΛΑΣΣΙΝΑ
F3 ΜΠΑΚΑΛΙΑΡΟΣ (Gadus morhua)
F23 KΑΒΟΥΡΙ (Cancer pagurus)
F24 ΓΑΡΙΔΑ (Pandalus borealis)
F37 MΥΔΙ (Mytilus edulis)
F40 TOΝΟΣ (Thunnus albacares)
F41 ΣΟΛΩΜΟΣ (Salmo salar)
F59 ΧΤΑΠΟΔΙ (Octopus vulgaris)
F80 ΑΣΤΑΚΟΣ (Homarus gammarus)
F204 ΠΕΣΤΡΟΦΑ (Oncorhynchus mykiss)
F205 ΡΕΓΓΑ (Clupea harengus)
F258 ΚΑΛΑΜΑΡΙ (Loligo sp.)
F264 ΧΕΛΙ (Anguilla anguilla)
F290 ΣΤΡΕΙΔΙ (Ostrea edulis)
F303 ΙΠΠΟΓΛΩΣΣΟΣ (Hippoglossus hippoglossus)
F308 ΣΑΡΔΕΛΑ (Sardina pilchardus)
F313 ΑΝΤΖΟΥΓΙΑ (Engraulis encrasicolus)
F314 ΣΑΛΙΓΓΑΡΙ (Helix aspersa)
F320 ΚΑΡΑΒΙΔΑ (Astacus astacus)
F333 ΚΥΠΡΙΝΟΣ (Cyprinus sp.)

ΤΡΟΦΙΜΑ – ΓΑΛΑΚΤΟΚΟΜΙΚΑ
F2 ΓΑΛΑ ΑΓΕΛΑΔΟΣ
F76 Α-ΛΑΚΤΑΛΒΟΥΜΙΝΗ
F77 Β-ΛΑΚΤΟΣΦΑΙΡΙΝΗ
F78 KΑΖΕΪΝΗ ΓΑΛΑΚΤΟΣ
F81 TΥΡΙ ΤΥΠΟΥ ΤΣΕΝΤΑΡ
F82 ΤΥΡΙ ΤΥΠΟΥ ΡΟΚΦΟΡ
F231 ΓΑΛΑ (ΒΡΑΣΜΕΝΟ / UHT)
F300 ΓΑΛΑ ΚΑΤΣΙΚΙΣΙΟ

ΤΡΟΦΙΜΑ – ΚΡΕΑΤΙΚΑ
F26 XΟΙΡΙΝΟ ΚΡΕΑΣ (Sus sp.)
F27 ΜΟΣΧΑΡΙΣΙΟ ΚΡΕΑΣ (Bos sp.)
F83 ΚΟΤΟΠΟΥΛΟ (Gallus sp.)
F88 AΡΝΙΣΙΟ ΚΡΕΑΣ (Ovis sp.)
F284 ΓΑΛΟΠΟΥΛΑ (Meleagris gallopavo)

ΤΡΟΦΙΜΑ – ΑΒΓΑ
F1 ΑΣΠΡΑΔΙ ΑΥΓΟΥ
F75 KΡΟΚΟΣ AΥΓΟΥ
F245 ΑΥΓΟ ΟΛΟΚΛΗΡΟ

ΤΡΟΦΙΜΑ – ΔΙΑΦΟΡΑ
F45 MΑΓΙΑ (Saccharomyces cerevisiae)
F93 KΑΚΑΟ (Theobroma cacao)
F212 ΜΑΝΙΤΑΡΙ (Agaricus hortensis)
F221 ΚΑΦΕΣ (Coffea sp.)
F222 ΤΣΑΙ ΜΑΥΡΟ (Camellia sinensis)
F247 ΜΕΛΙ
F297 ΑΡΑΒΙΚΟ ΚΟΜΜΙ - E414 (Acacia sp.)